…genome can be transmitted to new generations of cells, so gene editing therapies can be used in tissues with a higher turnover rate, such as the liver in young children….
…out the disease genome for conditions causing blindness is critical to figuring out which pathologies can be targeted,” said Boparai. Moreover, the accuracy of the delivery as well as its…
…field. However, he highlighted the difficulty in getting rid of the virus from the body: “The problem is that HIV is inserted into the genome of infected cells like long-lived…
Could your nose lead to major discoveries in antibiotic production? Genome mining of nose bacteria has revealed a new powerful antibiotic. Functional genomics offers a powerful tool for the isolation…
…containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease; and a first-of-its-kind metallo-CRISPR library of custom single guide RNAs. Blacksmith Medicines also has…
…the pet, in 1997. Kac’s controversial piece, Alba, was a genetically-modified rabbit whose genome was engineered to have the green fluorescent protein (GFP) gene found in jellyfish, that fluoresces green…
…predicted protein structures are AI-generated, and based on the complete sequence of the genome of the epidemic strain in May 2022, the whole proteome of the 2018 West African virus…
…Loo Lin School of Medicine, both at the National University of Singapore (NUS), and the Genome Institute of Singapore at the Agency for Science, Technology and Research (A*STAR), are seeking…
…This year, the day will be marked by more than 600 events in 106 countries. Replay and The University of Texas MD Anderson Cancer Center create Syena Replay, a genome…
…and multinational biopharma Genevant Sciences have agreed to combine Editas’ CRISPR Cas12a genome editing systems with Genevant’s lipid nanoparticle (LNP) technology to develop gene editing medicines. The deal will see…
…gene editing Recent funding: $40 million public offering North Carolina-based company Precision Biosciences is developing its ARCUS genome editing to treat HBV, the first and only clinical-stage gene editing therapy for…
…for gene therapies to correct errors in the genome. Sarepta, which paid $40M (€33M) upfront and agreed to up to $500M (€407M) in milestones to secure European rights to ezutromid,…